Advertisement

Benefits of Beta-Blockade in Sepsis and Septic Shock: A Systematic Review

  • Young R. LeeEmail author
  • Michael Sadanand Seth
  • Dylan Soney
  • Hanyu Dai
Systematic Review
  • 37 Downloads

Abstract

Background

Sepsis and septic shock are inflammatory disorders associated with high rates of mortality. Patients with sepsis and septic shock frequently become tachycardic as a result of the utilization of vasopressor therapy and cardiac overcompensation owing to hypotension, predisposing patients to an increased risk of atrial fibrillation. Previously, it was thought that beta-blocker therapy in patients with sepsis would exacerbate hypotension; however, recent studies have shown that may not be the case.

Objective

This review aims to ascertain whether beta-blocker therapy reduces heart rate in patients with sepsis without a corresponding decrease in blood pressure, and if beta-blockade has a beneficial effect on mortality.

Methods

Several databases including Cochrane, EMBASE, PubMed, SCOPUS, and Web of Science were scoured for trials pertaining to the utilization of beta-blockers in sepsis and septic shock, and trials that were either prospective or controlled were included in this review.

Results

In the initial search, 1839 articles were found, and those were subsequently reduced to 14 trials (five randomized controlled trials, nine non-randomized trials) that were deemed appropriate for inclusion in this review. All included trials displayed beneficial effects on heart rate without any detriments to blood pressure. Of the six trials that assessed mortality, four showed substantial benefits.

Conclusion

The majority of the trials assessed in this review displayed beneficial results for beta-blocker use in patients with sepsis. However, owing to the deficit of large-scale randomized controlled trials addressing this topic, further research is needed to ensure the veracity of these results.

Notes

Acknowledgements

The authors acknowledge Nguyen Le for her assistance in assessing articles for this review.

Compliance with Ethical Standards

Funding

No sources of funding were received for the preparation of this systematic review.

Conflict of interest

Young R. Lee, Michael Sadanand Seth, Dylan Soney, and Hanyu Dai have no conflicts of interest that are directly relevant to the content of this systematic review.

References

  1. 1.
    Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009–2014. JAMA. 2017;318(13):1241–9.  https://doi.org/10.1001/jama.2017.13836.Google Scholar
  2. 2.
    Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003;31:1250–6.Google Scholar
  3. 3.
    Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–55.  https://doi.org/10.1378/chest.101.6.1644.Google Scholar
  4. 4.
    Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045.  https://doi.org/10.1038/nrdp.2016.45.Google Scholar
  5. 5.
    Suzuki T, Suzuki Y, Okuda J, et al. Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis. J Intensive Care. 2017;5:22.  https://doi.org/10.1186/s40560-017-0215-2.Google Scholar
  6. 6.
    Kuipers S, Klein Klouwenberg PM, Cremer OL. Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review. Crit Care. 2014;18(6):688.  https://doi.org/10.1186/s13054-014-0688-5.Google Scholar
  7. 7.
    Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552.  https://doi.org/10.1097/CCM.0000000000002255.Google Scholar
  8. 8.
    Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med. 2004;32(9):1928–48.  https://doi.org/10.1097/01.CCM.0000139761.05492.D6.Google Scholar
  9. 9.
    Sander O, Welters ID, Foëx P, Sear JW. Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications. Crit Care Med. 2005;33(1):81–8.  https://doi.org/10.1097/01.CCM.0000150028.64264.14.Google Scholar
  10. 10.
    Chacko CJ, Gopal S. Systematic review of use of β-blockers in sepsis. J Anaesthesiol Clin Pharmacol. 2015;31(4):460–5.  https://doi.org/10.4103/0970-9185.169063.Google Scholar
  11. 11.
    Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. http://www.handbook.cochrane.org. Accessed 13 Feb 2019.
  12. 12.
    Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.  https://doi.org/10.1371/journal.pmed1000097.Google Scholar
  13. 13.
    Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock a randomized clinical trial. JAMA. 2013;310(16):1683–91.  https://doi.org/10.1001/jama.2013.278477.Google Scholar
  14. 14.
    Yang S, Liu Z, Yang W, et al. Effects of the β-blockers on cardiac protection and hemodynamics in patients with septic shock: a prospective study [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014;26(10):714–7.  https://doi.org/10.3760/cma.j.issn.2095-4352.2014.10.007.Google Scholar
  15. 15.
    Wang Z, Wu Q, Nie X, Guo J, Yang C. Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial. Clin Drug Investig. 2015;35(11):707–16.  https://doi.org/10.1007/s40261-015-0325-3.Google Scholar
  16. 16.
    Xinqiang L, Weiping H, Miaoyun W, et al. Esmolol improves clinical outcome and tissue oxygen metabolism in patients with septic shock through controlling heart rate [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27(9):759–63.  https://doi.org/10.3760/cma.j.issn.2095-4352.2015.09.012.Google Scholar
  17. 17.
    Wang S, Li M, Duan J, et al. Effect of esmolol on hemodynamics and clinical outcomes in patients with septic shock [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017;29(5):390–5.  https://doi.org/10.3760/cma.j.issn.2095-4352.2017.05.002.Google Scholar
  18. 18.
    Berk JL, Hagen JF, Maly G, Koo R. The treatment of shock with beta adrenergic blockade. Arch Surg. 1972;104(1):46–51.Google Scholar
  19. 19.
    Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis. Surgery. 2006;139(5):686–94.  https://doi.org/10.1016/j.surg.2005.10.010.Google Scholar
  20. 20.
    Balik M, Rulisek J, Leden P, et al. Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. Wien Klin Wochenschr. 2012;124:552–6.  https://doi.org/10.1007/s00508-012-0209-y.Google Scholar
  21. 21.
    Morelli A, Donati A, Ertmer C, et al. Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. J Crit Care Med. 2013;41(9):2162–8.  https://doi.org/10.1097/CCM.0b013e31828a678d.Google Scholar
  22. 22.
    Tao Y, Jingyi W, Xiaogan J, Weihua L, Xiaoju J. Effect of esmolol on fluid responsiveness and hemodynamic parameters in patients with septic shock [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27(11):885–9.  https://doi.org/10.3760/cma.j.issn.2095-4352.2015.11.004.Google Scholar
  23. 23.
    Du W, Wang XT, Long Y, Liu DW. Efficacy and safety of esmolol in treatment of patients with septic shock. Chin Med J. 2016;129:1658–65.  https://doi.org/10.4103/0366-6999.185856.Google Scholar
  24. 24.
    Morelli A, Singer M, Ranieri VM, et al. Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study. Intensive Care Med. 2016;42:1528–34.  https://doi.org/10.1007/s00134-016-4351-2.Google Scholar
  25. 25.
    Shang X, Wang K, Xu J, et al. The effect of esmolol on tissue perfusion and clinical prognosis of patients with severe sepsis: a prospective cohort study. Biomed Res Int. 2016;2016:1–7.  https://doi.org/10.1155/2016/1038034.Google Scholar
  26. 26.
    Fuchs C, Wauschkuhn S, Scheer C, et al. Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. Br J Anaesth. 2017;119(4):616–25.  https://doi.org/10.1093/bja/aex231.Google Scholar
  27. 27.
    Gorczynski RJ. Basic pharmacology of esmolol. Am J Cardiol. 1985;56(11):3F–13F.  https://doi.org/10.1016/0002-9149(85)90910-5.Google Scholar
  28. 28.
    Wiest DB, Haney JS. Clinical pharmacokinetics and therapeutic efficacy of esmolol. Clin Pharmacokinet. 2012;51(6):347–56.  https://doi.org/10.2165/11631590-000000000-00000.Google Scholar
  29. 29.
    Lindsay CA, Barton P, Lawless S, et al. Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. J Pediatr. 1998;132(2):329–34.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pharmacy Practice, School of PharmacyTexas Tech University Health Sciences CenterAbileneUSA

Personalised recommendations